IL162666A0 - A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof - Google Patents

A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof

Info

Publication number
IL162666A0
IL162666A0 IL16266602A IL16266602A IL162666A0 IL 162666 A0 IL162666 A0 IL 162666A0 IL 16266602 A IL16266602 A IL 16266602A IL 16266602 A IL16266602 A IL 16266602A IL 162666 A0 IL162666 A0 IL 162666A0
Authority
IL
Israel
Prior art keywords
preparation
pharmaceutical formulation
stable pharmaceutical
paroxetine hydrochloride
paroxetine
Prior art date
Application number
IL16266602A
Other languages
English (en)
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IL162666A0 publication Critical patent/IL162666A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL16266602A 2001-12-28 2002-12-27 A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof IL162666A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34412001P 2001-12-28 2001-12-28
US36635102P 2002-03-21 2002-03-21
PCT/US2002/041429 WO2003057150A2 (en) 2001-12-28 2002-12-27 A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof

Publications (1)

Publication Number Publication Date
IL162666A0 true IL162666A0 (en) 2005-11-20

Family

ID=26993762

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16245802A IL162458A0 (en) 2001-12-28 2002-12-27 A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
IL16266602A IL162666A0 (en) 2001-12-28 2002-12-27 A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL16245802A IL162458A0 (en) 2001-12-28 2002-12-27 A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof

Country Status (6)

Country Link
US (5) US7396542B2 (xx)
EP (2) EP1465601A4 (xx)
AU (2) AU2002359857B8 (xx)
CA (2) CA2470496A1 (xx)
IL (2) IL162458A0 (xx)
WO (2) WO2003057151A2 (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208932A1 (en) * 2003-04-17 2004-10-21 Ramachandran Thembalath Stabilized paroxetine hydrochloride formulation
EP1675574A2 (en) * 2003-10-08 2006-07-05 Ranbaxy Laboratories, Ltd. Pharmaceutical compositions of paroxetine containing microcrystalline cellulose, prepared by wet granulation
TW200526664A (en) * 2003-11-21 2005-08-16 Schering Corp Phosphodiesterase V inhibitor formulation
CN100558252C (zh) * 2004-03-08 2009-11-11 维他麦食品（福建）有限公司 压缩麦片的制造方法及其压缩麦片
WO2005107716A1 (en) * 2004-03-25 2005-11-17 Cadila Healthcare Limited Controlled release paroxetine-containing tablets based on a core and a coating
US20050244492A1 (en) * 2004-04-30 2005-11-03 Mehra Dev K Rapidly disintegrating tablets comprising titanium dioxide
EP1726591B1 (en) * 2005-05-26 2008-09-10 Apotecnia , S.A. Process for manufacturing paroxetine hydrochloride hemihydrate
WO2007012968A2 (en) * 2005-07-29 2007-02-01 Aurobindo Pharma Ltd Stable dosage form of an antidepressant
WO2007035816A2 (en) * 2005-09-20 2007-03-29 Dr. Reddy's Laboratories Ltd. Paroxetine compositions
US8703191B2 (en) * 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
JP2011519873A (ja) * 2008-05-07 2011-07-14 ハー・ルンドベック・アクチエゼルスカベット 認知欠損を治療する方法
US20090285889A1 (en) * 2008-05-14 2009-11-19 Capricom Pharma Inc. Modified release formulations of dihydropyridine compounds and methods of making same
CA2732613A1 (en) * 2008-10-03 2010-04-08 H. Lundbeck A/S Oral formulation
MX2011003740A (es) 2008-10-07 2011-05-02 Astrazeneca Uk Ltd Formulacion farmaceutica - 514.
WO2010088385A1 (en) 2009-01-30 2010-08-05 Sepracor Inc. Coated tablets of 6-(5-chloro-2-pyridyl) -5-[ (4-methyl-1-piperazinyl) carbonyloxy]-7-oxo-6, 7-dihydro-5h-pyrrol o [3,4-b] pyrazine and methods for measuring effectiveness of coating
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
SG11202009174WA (en) * 2018-03-22 2020-10-29 Komipharm Int Australia Pty Ltd Pharmaceutical composition comprising meta arsenite and method of manufacture
CN110037995B (zh) * 2019-04-17 2021-07-06 石家庄龙泽制药股份有限公司 一种稳定的盐酸帕罗西汀片剂及其制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US48600A (en) * 1865-07-04 Improvement in horse-powers
US65301A (en) * 1867-05-28 Improved compound foe coating oil-cloths
US8896A (en) * 1852-04-20 Hame-ttjg
US35145A (en) * 1862-05-06 Improvement in spindles for spinning
US15066A (en) * 1856-06-10 Machine for rubbing and polishing painted cloth
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
DE3688827T2 (de) 1985-10-25 1994-03-31 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel.
US4721196A (en) * 1986-01-29 1988-01-26 Sundstrand Corporation Overtravel stop
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
CA2096853A1 (en) * 1990-11-24 1992-05-25 Anthony Michael Johnson Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5856493A (en) * 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
EP0991576B1 (en) 1997-06-26 2002-10-16 Trexel, Inc. Microcellular container and method for storing products at low temperature in such a container
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
JP3230468B2 (ja) * 1997-09-11 2001-11-19 村田機械株式会社 ブレイディング用マンドレルの引っ張り治具と細長いブレイディング成形物の成形方法
ZA989251B (en) 1997-10-17 2000-04-10 Lilly Co Eli Potentiation of pharmaceuticals.
US6228864B1 (en) * 1997-10-28 2001-05-08 Vivus, Inc. Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
HUP0101627A3 (en) 1998-04-14 2003-02-28 Gen Hospital Corp Boston Pharmaceutical compositions for treating neuropsychiatric disorders
US6168805B1 (en) * 1998-05-07 2001-01-02 Endo Pharmaceuticals, Inc. Aqueous process for manufacturing paroxetine solid dispersions
GB9812941D0 (en) * 1998-06-16 1998-08-12 Smithkline Beecham Plc Method of treatment
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
WO2000025753A2 (en) 1998-11-02 2000-05-11 Alza Corporation Controlled delivery of active agents
GB9826180D0 (en) 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
AU5152900A (en) * 1999-05-24 2000-12-12 Purepac Pharmaceutical Co. A pharmaceutical composition containing an active agent that is maintained in solid amorphous form and method of making the same
JP2001304057A (ja) * 2000-04-27 2001-10-31 Tigers Polymer Corp 内燃機関の吸気装置
US6660298B1 (en) * 2000-07-27 2003-12-09 Pentech Pharmaceuticals, Inc. Paroxetine tablets and capsules
NZ523902A (en) * 2000-08-28 2004-05-28 Synthon Bv Paroxetine compositions and processes for making the same
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
DK200100341A (da) 2001-03-02 2002-09-03 Gea Farmaceutisk Fabrik As Fremgangsmåde til fremstilling af farmaceutiske tabletter indeholdende paroxetinhydrochlorid-anhydrat

Also Published As

Publication number Publication date
EP1465601A4 (en) 2006-02-15
CA2470496A1 (en) 2003-07-17
EP1465601A2 (en) 2004-10-13
US20030158230A1 (en) 2003-08-21
AU2002360775A1 (en) 2003-07-24
US20050059701A1 (en) 2005-03-17
WO2003057150A3 (en) 2006-06-08
US20080187584A1 (en) 2008-08-07
US20050191350A1 (en) 2005-09-01
WO2003057151A2 (en) 2003-07-17
WO2003057151A3 (en) 2004-01-08
AU2002360775B9 (en) 2008-07-24
US7357945B2 (en) 2008-04-15
AU2002360775B2 (en) 2008-06-19
AU2002359857A1 (en) 2003-07-24
EP1575478A2 (en) 2005-09-21
US20030144324A1 (en) 2003-07-31
CA2471715A1 (en) 2003-07-17
US7138137B2 (en) 2006-11-21
AU2002359857B8 (en) 2009-01-08
WO2003057150A2 (en) 2003-07-17
AU2002359857B2 (en) 2008-12-11
IL162458A0 (en) 2005-11-20
US7396542B2 (en) 2008-07-08

Similar Documents

Publication Publication Date Title
IL162666A0 (en) A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
HUP0400281A3 (en) Pharmaceutical compositions of adsorbates of amorphous drug and process for their preparation
IL162293A0 (en) Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
HUP0203451A3 (en) Pharmaceutical compositions of anti-tubercular drugs and process for their preparation
HUP0303800A3 (en) Pharmaceuticals and dosage forms of epothilones for oral administration
HUP0401238A3 (en) Pharmaceutical dosage form of amorphous nelfinavir mesylate and process for its preparation
HUP0303891A3 (en) Pharmaceutically active piridine derivatives, process for their preparation and pharmaceutical compositions containing them
IL149618A0 (en) Pharmaceutical compositions comprising thiazolidinedione and process for preparation thereof
IL166489A (en) Oral dosage form in single-dose administration containing at least two layers for the administration and use of flipridone
HK1067626A1 (en) Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient
PL396568A1 (pl) Krystaliczny bursztynian O-demetylo-wenlafaksyny, kompozycja farmaceutyczna, farmaceutyczna postać dawkowania, doustna postać dawkowania, zastosowanie oraz sposób wytwarzania krystalicznego bursztynianu O-demetylo-wenlafaksyny
EP1250127A4 (en) METHOD OF ADMINISTERING A MEDICAL AEROSOL FORMULATION
HK1140487A1 (en) Pharmaceutical compositions containing crystalline form (i) of lercanidipine hydrochloride (i)
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
SI1430020T1 (sl) Kvaternarne amonijeve soli omega-aminoalkilamidov r-2-aril-propionskih kislin in farmacevtski sestavki, ki jih vsebujejo
IL159217A0 (en) An oral pharmaceutical formulation comprising a basic pharmaceutically active ingredient having ph-dependent solubility, a process for the manufacture thereof and use thereof in medicine
HRP20030858A2 (en) Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency
HUP0401694A3 (en) Crystal forms of a hydrochloride salt of a hydroxynorephedrine derivative, pharmaceutical compositions comprising thereof and use
HUP0400386A3 (en) Tablet comprising cetirizine and pseudoephedrine and its use for preparation of pharmaceutical compositions
IL164903A0 (en) Processes for preparation of polymorphic form II of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
HUP0401369A3 (en) Pharmaceutical formulation comprising (r)-bicalutamide, process for its preparation and use thereof
HUP0203842A3 (en) Controlled release pharmaceutical composition containing tramadol hydrochloride and method for its preparation
SI1581258T1 (sl) Farmacevtska formulacija in postopek za njeno izdelavo
HUP0401161A3 (en) Solvates of lercanidipine hydrochloride and new crystalline forms of lercanidipine hydrochloride, process for their preparation and pharmaceutical compositions containing the crystalline forms
HUP0200913A3 (en) Isoindoindololone derivatives process for their preparation and pharmaceutical compositions containing them